Zelluna

Zelluna is a pioneering biotechnology research company focused on the development of innovative allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. Zelluna is dedicated to creating safe, efficient, and durable cancer responses through a portfolio of tumor-specific TCRs designed to guide NK cells. The company's commitment to advancing cancer treatment positions it as a key player in the immunooncology field.

Zelluna Immunotherapy is leveraging cutting-edge T cell receptor technologies and adoptive cell therapy to address the challenges of treating solid tumors. By focusing on allogeneic TCR-NK therapies, Zelluna aims to overcome the limitations of traditional cancer treatments and improve patient outcomes. With a strong emphasis on research and development, Zelluna is poised to make significant contributions to the future of cancer care.

Zelluna continues to innovate and expand its capabilities in biotechnology research. The company’s work in immunooncology and immunotherapy is setting new standards for cancer treatment. We invite the management team at Zelluna to create a customized and exclusive company showcase and product listing on our platform to further enhance their commercial development.